Results 1 to 5 of 5

Thread: MS reversed in lab

  1. #1

  2. #2
    DA, thanks for posting this news report. It is indeed an interesting development. Because the results are fairly complicated and may be relevant to MS and spinal cord injury, let me summarize the finding and try to explain why it is important.

    One of the authors of the paper is Hans Keirstead (who does spinal cord injury research) at the Reeve-Irvine Center at the University of California at Irvine. They reported that antibodies against a molecule called CXCL10 improves function in a viral model of demyelination in mice.

    The original full-text article can be accessed at http://www.jimmunol.org/cgi/content/...y=pH31T7d3v4OQ.


    MS slowed and reversed
    Posted 10/18/2001 - 6:59AM, by hanser
    ...And no this isn't about Microsoft. The BBC reports that scientists believe that it might be possible to halt and even reverse the effects of multiple sclerosis by deactivating chemicals called chemokines that can cause damage to the protective coating of nerves in the brain and spinal cord. It is this damage to the myelin sheath that causes the common symptoms of weakness and paralysis.
    It is caused by a malfunction of the immune system which turns on the body itself and attacks it. Nobody knows what triggers this malfunction, however research has shown that the cerebrospinal fluid found in the central nervous system of MS patients often contains high levels of chemokines.
    These chemicals play a large role in mobilizing the cells of the immune system to attack the myelin. The researchers, led by Dr Thomas Lane, from the University of California, Irvine, tested the theory that targeting chemokines, or the receptors that detect them, might slow down or halt the attack on the myelin, giving the nerve coating a chance to recover.
    New Scientist magazine reports that the team created antibodies that bind to a chemokine called CXCL10 and inactivate it. They targeted CXCL10 specifically because previous studies have shown that levels of the chemical rise sharply during MS attacks. When the antibodies were injected into mice with a condition similar to MS, they helped to slow demyelination, and even appeared to allow myelin to regrow. As a result, mice that were crippled were able to walk again. However, the reversal of symptoms was not complete and despite continued injections the effects lasted only a few days.
    The big question now is will it work on humans? Dr. Richard Ransohoff, an expert in chemokines and MS at the Lerner Research Institute in Cleveland, Ohio, said further tests were needed to see if the same results could be repeated in humans.

    "In terms of treating the inflammation aspects, Lane's work is as promising as anything one can imagine."
    So, what is CXCL10? It turns out that this is a protein that is inducible by interferon gamma, which many of you recognize is one of the cytokines that plays a role in the body's defense against infections and several forms of interferon are approved for treating MS in humans, e.g. betaseron. A recent paper reported that CXCL10 controls T-cell accumulation in the central nervous system.

    CXCL10 (IFN-gamma-Inducible Protein-10) Control of Encephalitogenic CD4(+) T Cell Accumulation in the Central Nervous System During Experimental Autoimmune Encephalomyelitis
    Fife BT, Kennedy KJ, Paniagua MC, Lukacs NW, Kunkel SL, Luster AD, Karpus WJ
    The Journal of Immunology 2001 Jun 15;166(12):7617-7624
    What does it mean? The authors demonstrate an important role for the immune system protein CXCL10 in recruiting and accumulating inflammatory cells during the development of an MS-like disease in mice.
    This is an arena where scientists in spinal cord injury are beginning to learn from scientists in multiple sclerosis research. For the longest time, people like myself thought that all immune and inflammatory responses to the spinal cord are bad. So, we did not pay much attention to myriads of different kinds of lymphocytes that were being reported in the MS and the AIDS literature. However, the work of Michal Schwartz has changed this because she showed that activated macrophages and then activated lymphocytes may be beneficial in spinal cord injury. It is clear that activated cells are not all the same or beneficial. Furthermore, the work of Moses Rodriguez and Sam David has shown that immune antibodies may be beneficial for remyelinating and regenerating the spinal cord.

    So, it would appear that CXCL10 may well be an important target of therapeutic vaccine approach to treatment of spinal cord injury.

    Wise.

  3. #3
    Senior Member DA's Avatar
    Join Date
    Jul 2001
    Location
    beaumont tx usa
    Posts
    32,389
    this is the kind of crap that pisses me off.

    "The big question now is will it work on humans? Dr. Richard Ransohoff, an expert in chemokines and MS at the Lerner Research Institute in Cleveland, Ohio, said further tests were needed to see if the same results could be repeated in humans."

    noticed how they go from breakthrough to human trials. why is it that sci researchers can not do the same. sci researchers feel the need to test it in apes and monkeys and more mice and chickens. that aint enough, they next gotta have the latest in new buildings and age the therapy in a dark closet like its some kind of wine. i can swear the motto of sci researchers is "do in 10 years what you can do in 1 year."

    [This message was edited by DA on October 22, 2001 at 06:25 PM.]

  4. #4
    Hey, DA, this is a treatment for MS. This is a form of anti-inflammatory therapy. The antibody is preventing activated lymphocytes from getting into the spinal cord and causing demyelination.


    The next step to get the treatment into human clinical trial is to make the human antibody against CXC10. Remember how long it is taking to get IN-1 to the point where it can be given to humans?

    To make it happen fast, they have to find a company to do that. I suspect that this is something that Novartis (now that they are experienced with getting IN-1 going) and several other companies would be interested in investing.

    Things can move very fast if enough money is poured into the antibody production or they can move very slowly. They will need to make sure that the humanized antibody works in at least one rodent and one large animal species before they can take it to clinical trial.

    Wise.

  5. #5
    Senior Member DA's Avatar
    Join Date
    Jul 2001
    Location
    beaumont tx usa
    Posts
    32,389
    i know its for ms. i was pointing out the black and white attitude and procedure of ms reseachers vs sci researchers.

    btw, with money being poured in or without the money. cxcl10 will not take a fraction of the time its taking in-1.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •